AstraZeneca completes $445 million Texas facility expansion

AstraZeneca announced the completion of a $445 million expansion of its manufacturing facility in Coppell, Texas, which will double production capacity for Lokelma, a treatment for hyperkalemia.

The expanded facility includes a new 9,000 square foot building with two additional manufacturing lines, enhanced laboratory testing capabilities, warehousing, and administrative space. The Coppell site serves as the sole global manufacturing facility for Lokelma, supplying more than 50 countries worldwide.

The facility currently employs more than 250 people. The expansion is part of AstraZeneca's $50 billion investment in US research and development and manufacturing over five years, announced in July 2025.

"Our manufacturing facility in Coppell serves as both a critical pillar in global healthcare and has played an important role in supporting the local workforce over the past 10 years," said Jim Fox, Senior Vice President, Americas Supply Operations at AstraZeneca.

The Texas expansion follows a recent groundbreaking at AstraZeneca's manufacturing facility in Albemarle County, Virginia. Both projects are components of the company's broader US investment strategy.

AstraZeneca operates 19 research and development, manufacturing and commercial sites across the United States, employing more than 25,000 people. The company reported creating approximately $20 billion in overall value to the American economy in 2025.

The information is based on an AstraZeneca press release statement.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Popular stocks with increasing option volume: SPCX MSTR PLTR MU HOOD MRNA SOFI BABA INTC WMT
• Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.